Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P515 Comparability of upadacitinib pharmacokinetics in Japanese and non-Japanese subjects with ulcerative colitis with the extended-release formulation

ECCO'20 Vienna

Year: 2020
Authors:

S. Stodtmann1, A. Friedel1, W. Zhou2, M.E. MOHAMED3

1AbbVie, Clinical Pharmacology and Pharmacometrics, Ludwigshafen, Germany, 2Immunology Development, AbbVie, North Chicago, USA, 3Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, USA

P516 Daily consumers of drip-filtered coffee have a decreased risk of developing late-onset Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

L. Widbom1, J. Hultdin1, K. Ekblom2, P. Karling3, L.M. Nilsson4

1Department of Medical Biosciences- Umeå University, Clinical Chemistry, Umeå, Sweden, 2Department of Research and Development- Region Kronoberg- Växjö, Clinical Chemistry, Växjö, Sweden, 3Department of Public Health and Clinical Medicine- Umeå University, Medicine, Umeå, Sweden, 4Department of Public Health and Clinical Medicine- Umeå University, Nutritional Research, Umeå, Sweden

P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

L. Hill1,2, J. Popov1,3, E. Hartung1, M. Moshkovich1,4, M. Figueiredo1,4, N. Pai1,5, McMaster Paediatric FMT Research Program

1Division of Gastroenterology and Nutrition, Department of Paediatrics- McMaster University, Hamilton, Canada, 2Department of Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South Africa, 3College of Medicine and Health, University College Cork, Cork, Ireland, 4Faculty of Health Sciences, McMaster University, Hamilton, Canada, 5Farncombe Family Digestive Health Research Institute, Department of Medicine- McMaster University, Hamilton, Canada

P518 Ulcerative colitis drug development success rates are higher than the industry average

ECCO'20 Vienna

Year: 2020
Authors:

G. Georgiev1, F. Hussain1, M. Copeman2, M. Delegge1, M.B. Gallagher1, T. Stewart1, W. Reinisch3

1IQVIA, Therapeutic Science and Strategy Unit, Raleigh, USA, 2IQVIA, Project Leadership, Raleigh, USA, 3Department of Gastroenterology, University of Vienna, Vienna, Austria

P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study

ECCO'20 Vienna

Year: 2020
Authors:

T. LEE1, L. Gilbert2, A. Srinivasan3, A. Lee4, D. van Langenberg3, C. Martin5, N. Ding1, M. Sparrow2

1Gastroenterology, St Vincent’s Hospital, Melbourne, Australia, 2Gastroenterology, Alfred Health, Melbourne, Australia, 3Gastroenterology, Eastern Health, Melbourne, Australia, 4Eastern Health, Radiology, Melbourne, Australia, 5Monash University, Epidemiology and Public Health, Melbourne, Australia

P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

M.I. Nicolás de Prado1, C. Iniesta Navalón2, R. Gomez Espin1, M. Gil Candel2, L. Serrano Díaz1, L. Rentero Redondo2, J.J. Martinez Crespo1

1Gastroenterology, Reina Sofia Hospital, Murcia, Spain, 2Pharmacology Department, Reina Sofia Hospital, Murcia, Spain

P521 Infection of the anal canal by human papillomavirus in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

V. Guzela1, C. Sobrado Júnior1, S. Nadal2, C.R. Nadal2, L.L. Villa3, A.P. Gonçalves1, L.R. Boarini1, S.C. Nahas1, I. Cecconello1

1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Gastroenterologia - Divisão de Coloproctologia, São Paulo, Brazil, 2Instituto de Infectologia Emílio Ribas, Departamento de Coloproctologia, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, Laboratório de Inovação em Câncer do Centro de Investigação Translacional em Oncologia, São Paulo, Brazil

P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy

ECCO'20 Vienna

Year: 2020
Authors:

R. Bornheimer1, S. Hass2, A. NAG3, G. Oster1

1Policy Analysis Inc., Health Economics and Outcomes Research, Brookline, USA, 2H. E. Outcomes, Health Economics and Outcomes Research, Los Angeles, USA, 3Shire- a Takeda company, Health Economics- Outcomes Research and Epidemiology, Lexington, USA

P523 Improvement of quality of life and continence in patients with distal ulcerative colitis treated by mesalazine: QUARTZ study

ECCO'20 Vienna

Year: 2020
Authors:

T. Paupard1, F. Gonzalez2, L. Siproudhis3, L. Peyrin-Biroulet4, Thierry Paupard

1Centre Hospitalier de Dunkerque, Gastroenterology, Dunkerque, France, 2Cabinet d’Hépato Gastroentérologie, Gastroenterology, Nîmes, France, 3CHU Pontchaillou, Gastroenterology, Rennes, France, 4CHU Brabois, Gastroenterology, Vandœuvre-lès-Nancy, France

P524 Administration and monitoring of biologic therapy in patients with inflammatory bowel disease: A national Danish survey

ECCO'20 Vienna

Year: 2020
Authors:

S. Volmar1, S. Wildt2,3, L.K. Munck2,3

1Section of Gastroenterology, Department of Internal Medicine, Zealand University Hospital Køge, DK-4600, Køge, Denmark, 2Section of Gastroenterology, Department of Internal Medicine, Zealand University Hospital Køge, DK-4600 Køge, Denmark, 3Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

P525 Rheumatoid arthritis treatment with filgotinib: Week 156 safety and efficacy data from a phase 2b open-label extension study

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, A. Kavanaugh2, R. Westhovens3, K. Winthrop4, S. Lee5, J. Greer6, A. DeZure6, D. An7, L. Ye7, J. Sundy6, L. Meuleners8, R. Alten9, M. Genovese10

1Galapagos NV, Clinical Development, Mechelen, Belgium, 2Department of Rheumatology, University of California, San Diego, CA, USA, 3Department of Rheumatology, University UZ Leuven, Leuven, Belgium, 4Department of Rheumatology, Oregon Health and Science University, Portland, OR, USA, 5Gilead Sciences Inc., Department of Medical Affairs, Foster City, CA, USA, 6Department of Clinical Research, Gilead Sciences Inc., Foster City, CA, USA, 7Department of Biostatistics, Gilead Sciences Inc., Foster City, CA, USA, 8Department of Biostatistics, Galapagos NV, Mechelen, Belgium, 9Department of Internal Medicine and Rheumatology, Schlosspark-Klinik, Berlin, Germany, 10Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA

P526 Body mass index and response to TNF-α inhibitors in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

F. Nordin1, B. Shadbolt2, K. Subramaniam1,3

1Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia, 2Health Analytics Research Centre, ACT Health, Canberra, Australia, 3Australian National University Medical School, Australian National University, Canberra, Australia

P527 A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

D. Tassone1, N. Ding2

1St Vincent’s Clinical School, University of Melbourne, Fitzroy, Australia, 2Department of Gastroenterology, St Vincent’s Hospital Melbourne, Fitzroy, Australia

P528 Response to biologic therapy in operated Crohn’s disease patients

ECCO'20 Vienna

Year: 2020
Authors:

A.C. Georgieva, A. Atanassova, M. Mirchev

Clinic of Gastroenterology, University Hospital St. Marina, Medical University, Varna, Bulgaria

P529 Natural history and management strategies of ulcerative colitis (UC) in a paediatric population: A 10-year review in a tertiary paediatric gastroenterology centre

ECCO'20 Vienna

Year: 2020
Authors:

M. Sonnino, A. Ocholi, A. ElZein, E. Saliakellis, L. Pensabene, O. Borrelli, F. Kiparissi

Department of Gastroenterology, Great Ormond Street Hospital, London, UK

P530 Cost-effectiveness of vedolizumab SC vs. adalimumab for moderately to severely active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

I. Diakite1, B. Schultz2, J. Carter1, S. Snedecor1, R. Turpin3

1Department of Gastroenterology, Pharmerit International, Bethesda, USA, 2Department of Gastroenterology, Takeda Pharmaceuticals, Deerfield, USA, 3Department of Gastroenterology, Takeda Pharmaceuticals U.S.A. Inc., Lake Zurich, USA

P531 A retrospective audit of the inflammatory bowel disease specialist nurse-led telephone advice service

ECCO'20 Vienna

Year: 2020
Authors:

C. Watters, W. Lloyd, M. Porteous, M. Mohamed, S. Kari, E. Nelson, R. Saravanan

Department of Gastroenterology, Silk House, Macclesfield District General Hospital, Macclesfield, UK

P532 Measuring endoscopic activity in patients treated with vedolizumab for ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

C. EMONT1, C. Gay2, A.L. Parmentier3, S. Koch4, S. Ambregna5, G. Claudé5, P. Sage5, P. Zhong4, C. Briot5, L. Vuitton4

1Department of Gastroenterology, Besançon University Hospital, Hospital of Haute-Saone, Besançon, Vesoul, France, 2Department of Gastroenterology, Lyon University Hospital, Lyon, France, 3Center of Clinical Methodology, Besançon University Hospital, Besançon, France, 4Department of Gastroenterology, Besançon University Hospital, Besançon, France, 5Department of Gastroenterology, Hospital of Haute-Saone, Vesoul, France

P533 Long-term quality of life after minimally invasive surgery for Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

I. Angriman, G. Bordignon, E. Sciuto, O. Zini, N. Bortoli, M. Gruppo, R. Bardini, C. Ruffolo, M. Scarpa

Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy

P534 Qualitative perspectives of parent and child participants from a trial of faecal microbiota transplant for paediatric ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

J. Popov1,2, E. Hartung1, L. Hill1,3, U. Chauhan4, N. Pai1,5, McMaster Paediatric FMT Research Program

1Division of Gastroenterology and Nutrition, Department of Paediatrics, McMaster University, Hamilton, Canada, 2College of Medicine and Health, University College Cork, Cork, Ireland, 3Department of Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South Africa, 4Division of Gastroenterology and Hepatology, Department of Medicine, McMaster University, Hamilton, Canada, 5Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Canada